

# TuÄÄŸe Nur YiÄenoÄlu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2376770/publications.pdf>

Version: 2024-02-01

40  
papers

355  
citations

932766

10  
h-index

839053

18  
g-index

40  
all docs

40  
docs citations

40  
times ranked

947  
citing authors

#	ARTICLE	IF	CITATIONS
1	The outcome of COVID-19 in patients with hematological malignancy. <i>Journal of Medical Virology</i> , 2021, 93, 1099-1104.	2.5	90
2	Convalescent plasma therapy in patients with COVID-19. <i>Transfusion and Apheresis Science</i> , 2021, 60, 102955.	0.5	52
3	Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1676-1682.	0.5	33
4	Convalescent plasma therapy in patients with COVID-19. <i>Journal of Clinical Apheresis</i> , 2020, 35, 367-373.	0.7	29
5	COVID-19 in hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 952-955.	1.3	24
6	Does microbial contamination influence the success of the hematopoietic cell transplantation outcomes?. <i>Transfusion and Apheresis Science</i> , 2016, 55, 125-128.	0.5	14
7	Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102855.	0.5	14
8	Convalescent plasma therapy in patients with COVID-19. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103017.	0.5	14
9	The outcome of COVID-19 in patients with hematological malignancy. <i>Journal of Medical Virology</i> , 2021, 93, 1255-1255.	2.5	12
10	Brentuximab vedotin consolidation therapy after autologous stem cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study. <i>Hematological Oncology</i> , 2021, 39, 498-505.	0.8	12
11	Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers. <i>Internal and Emergency Medicine</i> , 2022, 17, 135-139.	1.0	11
12	Covid-19 clinical course and blood groups: Turkish population-based study. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1659-1664.	0.4	9
13	Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. <i>Journal of Chemotherapy</i> , 2022, 34, 190-198.	0.7	7
14	Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations. <i>Medicine (United States)</i> , 2020, 99, e19627.	0.4	6
15	Inferior prognosis in poor mobilizing myeloma patients. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102722.	0.5	4
16	The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1857-1863.	0.5	3
17	Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma. <i>Leukemia Research</i> , 2021, 110, 106700.	0.4	3
18	The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 273-278.	0.5	2

#	ARTICLE	IF	CITATIONS
19	Old is bad? The effect of age on peripheral stem cell mobilization and transplantation outcomes. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103007.	0.5	2
20	Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 685-692.	0.4	2
21	Risk Adapted Management of Febrile Neutropenia and Early Cessation of Empirical Antibiotherapy in Hematopoietic Stem Cell Transplantation Setting. <i>Balkan Medical Journal</i> , 2017, 34, 132-139.	0.3	2
22	Evaluation of Risk Factors for Mortality in Febrile Neutropenia. <i>Journal of Infection in Developing Countries</i> , 2020, 14, 886-892.	0.5	2
23	Inotuzumab Ozogamicin Salvage Monotherapy for the Treatment of Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S192-S193.	0.2	1
24	The Relationship Between ABO and Rhesus Blood Groups and Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S192.	0.2	1
25	A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1499-1500.	0.5	1
26	Recovery of Symmetrical Peripheral Gangrene of Limbs in a Patient After Performing Hemoadsorption in Septic Shock. <i>Journal of Clinical Apheresis</i> , 2021, 36, 649-653.	0.7	1
27	The Outcome of Diffuse Large B Cell Lymphoma Patients in Adolescent and Young Adult Age Group. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 483-487.	0.7	1
28	Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103237.	0.5	1
29	Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythaemia Vera: a Multicentre Chart Review Study. <i>Turkish Journal of Haematology</i> , 2020, 37, 177-185.	0.2	1
30	Does Total Body Irradiation Have a Favorable Impact on Thrombocyte Engraftment as per Neutrophil Engraftment in Allogeneic Stem Cell Transplantation?. <i>Cureus</i> , 2021, 13, e19462.	0.2	1
31	Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S249-S250.	0.2	0
32	Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 929-932.	0.5	0
33	The effect of serum vitamin B12, folate, ferritin levels and transferrin saturation on stem cell mobilization in allogeneic donors. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102726.	0.5	0
34	Autologous Stem Cell Transplantation in Multiple Myeloma Patients Over 60 Years Old. <i>Medical Laboratory Technology Journal</i> , 2021, 7, 18.	0.1	0
35	Autologous Stem Cell Transplantation in Multiple Myeloma Patients Over 60 Years Old. <i>Medical Laboratory Technology Journal</i> , 2021, 7, 18.	0.1	0
36	Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?. <i>NamÄ±k Kemal TÄ±p Dergisi</i> , 2021, 9, 207-212.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Second allogeneic stem cell transplantation in acute leukemia patients: single-centre experience. Jurnal Teknologi Laboratorium, 2020, 9, 87-96.	0.4	0
38	The Outcome of Autologous Stem Cell Transplantation in Adolescent and Young Adult Patients with Multiple Myeloma. Eurasian Journal of Medicine and Oncology, 0, , .	1.0	0
39	Early Relapse After Autologous Stem Cell Transplantation in Multiple Myeloma is Still Prognostic in The Era of Novel Agents. Medical Laboratory Technology Journal, 2020, 6, 92.	0.1	0
40	Early Relapse After Autologous Stem Cell Transplantation in Multiple Myeloma is Still Prognostic in The Era of Novel Agents. Medical Laboratory Technology Journal, 2020, 6, 92.	0.1	0